Supernus Pharmaceuticals (SUPN) Cash & Equivalents (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Cash & Equivalents data on file, last reported at $184.9 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $184.9 million, up 59.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $184.9 million (up 59.58% YoY), and the FY2025 annual result was $128.4 million, up 85.27% from the prior year.
• Cash & Equivalents advanced to $184.9 million in Q1 2026 per SUPN's latest filing, from $128.4 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $184.9 million in Q1 2026 and troughed at $24.7 million in Q2 2023.
• A 5-year average of $99.3 million and a median of $95.0 million in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents plunged 85.75% in 2023, then surged 377.92% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $93.1 million in 2022, then retreated by 19.4% to $75.1 million in 2023, then retreated by 7.63% to $69.3 million in 2024, then jumped by 85.27% to $128.4 million in 2025, then soared by 43.93% to $184.9 million in 2026.
• Business Quant data shows SUPN's Cash & Equivalents at $184.9 million in Q1 2026, $128.4 million in Q4 2025, and $151.4 million in Q3 2025.